Home Newsfeeds Morgan Stanley Maintains Equal-Weight on TaskUs, Raises Price Target to $20

Morgan Stanley Maintains Equal-Weight on TaskUs, Raises Price Target to $20

Morgan Stanley analyst James Faucette maintains TaskUs (NASDAQ:TASK) with a Equal-Weight and raises the price target from $19 to $20.

byBenzinga Newsdesk

January 27, 2023

1 minute read

Morgan Stanley analyst James Faucette maintains TaskUs (NASDAQ:TASK) with a Equal-Weight and raises the price target from $19 to $20.

AbbVie Is ‘Successfully Positioned To Absorb Humira Biosimilar Erosion’: Analyst

By Vandana Singh

May 17, 1:47 PM

Cantor Fitzgerald initiates coverage on AbbVie with an Overweight rating and a $200 price target. AbbVie is set to manage Humira biosimilar erosion, drive growth with Skyrizi, Rinvoq, and emraclidine, and achieve a high single-digit CAGR from 2024 to 2029.

ABBV

Denny’s Enters Exclusive Test Agreement With Franklin Junction Providing Geographic Exclusivity For These Restaurants To Accelerate Denny’s Market Presence Through Its Innovative Host Kitchen Platform

By Benzinga Newsdesk

January 8, 5:20 PM

Denny's Corporation (the "Company") (NASDAQ:DENN), owner and operator of Denny's Inc. ("Denny's") and Keke's Inc. ("Keke's") today announced it has entered an expansive agreement with Franklin Junction, the global leader

DENN